Loading...
Please wait, while we are loading the content...
Similar Documents
Effect of Oral Losartan on Orthobiologics: Implications for Platelet-Rich Plasma and Bone Marrow Concentrate—A Rabbit Study
| Content Provider | MDPI |
|---|---|
| Author | Nakama, Gilberto Y. Gonzalez, Sabrina Matre, Polina Mu, Xiaodong Whitney, Kaitlyn E. Utsunomiya, Hajime Arner, Justin W. Philippon, Marc J. Ravuri, Sudheer Huard, Johnny |
| Copyright Year | 2020 |
| Description | Recent efforts have focused on customizing orthobiologics, such as platelet-rich plasma (PRP) and bone marrow concentrate (BMC), to improve tissue repair. We hypothesized that oral losartan (a TGF-β1 blocker with anti-fibrotic properties) could decrease TGF-β1 levels in leukocyte-poor PRP (LP-PRP) and fibrocytes in BMC. Ten rabbits were randomized into two groups (N = 5/group): osteochondral defect + microfracture (control, group 1) and osteochondral defect + microfracture + losartan (losartan, group 2). For group 2, a dose of 10mg/kg/day of losartan was administrated orally for 12 weeks post-operatively. After 12 weeks, whole blood (WB) and bone marrow aspirate (BMA) samples were collected to process LP-PRP and BMC. TGF-β1 concentrations were measured in WB and LP-PRP with multiplex immunoassay. BMC cell populations were analyzed by flow cytometry with CD31, CD44, CD45, CD34, CD146 and CD90 antibodies. There was no significant difference in TGF-β1 levels between the losartan and control group in WB or LP-PRP. In BMC, the percentage of CD31+ cells (endothelial cells) in the losartan group was significantly higher than the control group (p = 0.008), while the percentage of CD45+ cells (hematopoietic cells-fibrocytes) in the losartan group was significantly lower than the control group (p = 0.03). |
| Starting Page | 7374 |
| e-ISSN | 14220067 |
| DOI | 10.3390/ijms21197374 |
| Journal | International Journal of Molecular Sciences |
| Issue Number | 19 |
| Volume Number | 21 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2020-10-06 |
| Access Restriction | Open |
| Subject Keyword | International Journal of Molecular Sciences Cell Tissue Engineering Fibrosis Losartan Transforming Growth Factor-1 Beta (tgf-β1) Bone Marrow Concentrate (bmc) Leukocyte-poor Platelet-rich Plasma (lp-prp) |
| Content Type | Text |
| Resource Type | Article |